Bispecific antibodies to engage Vγ9Vδ2-T cells for cancer immunotherapy

Bispecific antibodies in cancer immunotherapyПодробнее

Drawn to Science | T-cell bispecific antibodiesПодробнее

Understanding Bispecific Antibody Immunotherapy for Cancer TreatmentПодробнее

Bispecific T-Cell Engager (BiTE) TherapyПодробнее

Bispecific Gamma-Delta T Cell Engagers for the Treatment of CancerПодробнее

Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell LymphomaПодробнее

Bispecific antibodies enable synthetic agonistic receptor T-cell therapy in melanomaПодробнее

Innovations from the therapeutics antibody space: obligate bispecific antibodies & T cell engagersПодробнее

What are the differences between CAR T-cell therapy and bispecific antibodies?Подробнее

What You Need to Know about Bispecific Antibody ImmunotherapyПодробнее

Bispecific Antibodies for T‐Cell Redirection TherapyПодробнее

The CAR T-cell strategy vs bispecific antibodiesПодробнее

Bispecific antibodies in lung cancerПодробнее

Moffitt Medical Minute (Ep. 43) - Bispecific Antibodies (BsAbs) in Cancer TreatmentПодробнее

How Is Bispecific Antibody Therapy Changing Myeloma Care?Подробнее

Bispecific Antibodies | High Impact Topic (HIT)Подробнее

Antibody-based and bispecific T-cell dependent therapiesПодробнее

What are bispecific antibodies?Подробнее

The Promise of NK Engager Bispecific Antibodies (with CSO Dr. Wei Li)Подробнее